Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q1 FY2026 Earnings Presentation
34 slides from Jubilant Ingrevia's earnings presentation, July 2025
Slide 1: Investor Presentation July 2025
Investor Presentation July 2025 Innovating for a Sustainable Future 1
Slide 2: Forward-looking statements and notes
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product
Slide 3: Chairman's message and markets update
“We are pleased to present the financial results for the first quarter of this fiscal year. Our specialty chemical businesses have continued to perform strongly, growing double digit YoY and with stable performance on QoQ basis. Our Chemical Intermediates business has started to recover marginally w
Slide 4: Business Update
Business Update: Specialty Chemicals saw stable volumes, with growth led by Pyridine and Diketene derivatives and CDMO sales. Pharma end-use sales posted strong YoY demand growth with steady pricing. Agriculture end-use segment showed modest volume gains, stable pricing, and normalized inventories.
Slide 5: Table of Contents
Table of Contents 0 6 Company Overview 1 3 Growth Roadmap 1 8 Q1’FY26 Highlights 2 5 Business Segments Update 5
Slide 6: Company Overview
Company Overview . Visuals of our New Diketene Derivatives Plant in Gajraula 6
Slide 7: Transformation into Forward Integrated Specialty Leader
Transformation into Forward Specialty Leader Expansion & Integration 2023 onwards Origin Diversification 2011 - 2023 1978 – 1990 1990 – 2011 • Expansion of Pyridine • Started as VAM • Forward integration into • Foray into Pyridine derivatives Organics Pyridine derivatives Chemistry • Foray into Dike
Slide 8: Specialty Chemicals, Nutrition & Health Solutions, Chemical Intermediates
1 2 3 Specialty Nutrition Chemical Chemicals & Health Solutions Intermediates • CDMO • Fine Chemicals • Animal Nutrition and Health Solutions • Acetic Anhydride • Acetaldehyde • Pyridine and Picolines • Human Nutrition Solutions • Ethyl Acetate • Bio Acetic Acid Globally #1 Globally #2 Globally #2 •
Slide 9: Nutrition & Health Solutions revenue mix
Consumer ROW Nutrition 5% 13% & Health Agro North Solutions 18% Pharma America 17% Specialty 32% 10% India Chemicals 56% 46% Europe Chemical Industrial 21% Intermediates 26% 37% Nutrition 17% 9
Slide 10: 2300+ people, 130+ products, 1500+ customers
Gajraula Bharuch Nira Savli Ambernath Uttar Pradesh, India Gujarat, India Maharashtra, India Gujarat, India Maharashtra, India Integrated facility for CDMO & Fine Chemicals Chemical Intermediates Animal Nutrition Microbial Control Specialty Chemicals & Nutrition and Chemical Facility & Health Soluti
Slide 11: R&D Centers, Scientists, PhDs
R&D Center G. Noida UP, India Pilot Plant at Gajraula UP, India 3 ~150 ~30 R&D Centers Scientists PhDs 11
Slide 12: Leadership team
SS Bhartia HS Bhartia Deepak Jain Chairman Co-Chairman & Whole CEO & MD Time Director 20 yrs exp Business Leaders Function Leaders Specialty Chemicals Nutrition & Health Chemical Intermediates Varun Gupta Vijay Kumar Srivastava Ambrish Dixit Ashish Kr. Sinha Himanshu Dhapola President, Chief Preside
Slide 13: Growth Roadmap
Growth Roadmap (Recap and Progress Update) 13
Slide 14: Pinnacle 3.4.5 growth path
We set out on an ambitious growth path — Pinnacle 345 wan INGREVIA & _—_—- uu, AD —-— times 5 Al times Kin year "All REVENUE EBITDA HORIZON
Slide 15: Pinnacle 3.4.5 growth pillars
PINNACLE3.4.5 PINNACLE 3.4.5 G R O W T H P I L L A R S New Growth Areas A Specialty Chemicals B Nutrition & Health solutions C Chemical Intermediates Pyridine & Picoline Animal Nutrition Acetic Anhydride Retain Global leadership (#1 position, cost leadership) Scale up Oilfield chemicals Feed Vit B3:
Slide 16: Key achievements by business
Today Business Tomorrow Key Achievements • Maintained global leadership and market share in Pyridine and Beta-Picoline Pyridine & Picoline • Increased SOW in AP/APQ across customers • 15%+ revenue growth in FY25; Maintained leadership across 36 Pyridine Derivatives • Good traction in Diketene Deriva
Slide 17: Pillars progress by quarter
Today Pillars Tomorrow Q1FY25 Q2FY25 Q3FY25 A Q4FY25 Q1FY26 Roadshows across EU/ Secured CDMO order Secured CDMO order Funnel expansion across In-process of launching of US/ Japan; 120+ from Agro Innovator #1 from Agro Innovator #2 Pharma/Agro/Semicon Human Nutrition pre-mixes Customer customer meet
Slide 18: Q1'FY26 Highlights
Q1’FY26 Highlights 18 18
Slide 19: End-market update: Pharma, Agrochem, Nutrition
PHARMA • Volumes remained steady across segments, especially in our core products in Fine Chemicals • The paracetamol segment remained muted given the low demand and utilization levels. • Prices remain stable (vs Q4’FY25) across various segments; Customers awaiting clarity on tariff situation AGROCH
Slide 20: Core product platforms continue to drive performance
• Pyridine & Picoline: Globally #1 position in P&P (only scaled non-Chinese player), QoQ volume Core product platforms continue to growth driving overall sales growth despite some price volatility drive performance; Acetyls portfolio • Niacinamide: Maintained leadership position in feed grade with i
Slide 21: Q1'FY26 financial summary
Particulars1 Q1'FY25 Q4'FY25 Q1'FY26 Q-o-Q Y-o-Y Total Revenue 1,024 1,051 1,038 -1% 1% Total EBITDA 119 155 153 -1% 29% EBITDA Margin (%) 12% 15% 15% Profit After Tax 49 74 75 1% 54% Profit After Tax Margin (%) 5% 7% 7% Basic and Diluted EPS (Rs.) 3.1 4.7 4.7 1% 54% Revenue & EBITDA during the quar
Slide 22: JVL EBITDA Key Drivers
JVL EBITDA Key Drivers 35.0% 153 160 151 30.0% 140 • Increasing revenue share of Specialty Chem + 125 Nutrition BUs 25.0% 119 120 • Increasing share of high-value products within 20.0% each BU portfolio e.g., increasing share of 100 14.8% 15.0% 13.0% cosmetic/food grade B3, higher growth from new 11
Slide 23: Segment-wise EBITDA Share
Segment-wise EBITDA Share (%) 6% 13% 10% 25% 27% 17% 36% 36% 14% 43% 40% 15% 48% 46% 45% 49% 16% 16% 7% 14% 5% 14% 8% 4% 13% 12% 76% 76% 72% 56% 59% 57% 52% 50% 46% 47% 46% 40% 43% Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Specialty Chemicals Nutritio
Slide 24: Segment EBITDA: Specialty, Nutrition, Intermediates
Specialty Chemicals Nutrition Chemical Intermediates EBITDA (Rs Cr.) EBITDA (Rs Cr.) EBITDA (Rs Cr.) Y.o.Y Growth 52% Y.o.Y Growth 8% Y.o.Y Growth -53% Q.o.Q Growth 1% Q.o.Q Growth -16% Q.o.Q Growth 63% 129 130 29 36 25 23 86 27% 27% 16% 17 14% 20% 12% 10 9% 4.4% 2.6% Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25
Slide 25: Business Segments Overview
Business Segments Overview 25
Slide 26: Specialty Chemicals: Pharma, Agrochemical, CDMO
1 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS - Continued improvement in demand observed Particulars1 Q1'FY25 Q4'FY25 Q1'FY26 Q-o-Q Y-o-Y - YoY demand growth remained strong Segment Revenue 431 487 478 -2% 11% % Share of Overall Revenue 42% 46% 46% Pharma - Steady pricing trend maintained EBITDA 86 129 1
Slide 27: Nutrition & Health Solutions: Feed B3, Choline
2 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS - Volumes were low as buyers delayed shipments, opting to maintain lower Particulars1 Q1'FY25 Q4'FY25 Q1'FY26 Q-o-Q Y-o-Y inventory levels Segment Revenue 186 190 179 -6% -4% Feed B3 - Overall Pricing witnessed modest softening % Share of Overall Revenue 18%
Slide 28: Chemical Intermediates: Volumes, Cost, Price
3 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS - Acetic Anhydride volumes saw an uptick during Particulars1 Q1'FY25 Q4'FY25 Q1'FY26 Q-o-Q Y-o-Y the quarter driven by recovery in agrochem Segment Revenue 408 375 381 2% -7% segments - Ethyl Acetate volumes remained a key area of % Share of Overall Revenue 4
Slide 29: Annexures
Ww UBILANT Increvia VT Been lA Nn ita)
Slide 30: Consolidated profit and loss statement
Particulars1 Q1'FY25 Q4'FY25 Q1'FY26 QoQ YoY Revenue from operations a) Sales/Income from operations 1010 1038 1029 -1% 2% b) Other operating income 14 13 9 -35% -39% Total revenue from operations 1024 1051 1038 -1% 1% Other income 10 8 11 34% 17% Total income 1034 1060 1049 -1% 1% Expenses a) Cost
Slide 31: Segment revenue and EBITDA summary
Particulars1 Q1'FY25 Q4'FY25 Q1'FY26 QoQ (%) YoY (%) Revenue Speciality Chemicals 431 487 478 (2%) 11% Nutrition & Health Solutions 186 190 179 (6%) (4%) Chemical Intermediates 408 375 381 2% (7%) Total Revenue from Operations 1,024 1,051 1,038 (1%) 1% Reported EBITDA 119 155 153 (1%) 29% Speciality
Slide 32: Debt and capex
Particulars1 30-Jun-24 31-Mar-25 30-Jun-25 Long Term Borrowings 450 453 448 Short Term Borrowings 291 303 360 Total Gross Debt 741 756 808 Cash & Equivalent 64 98 107 Total Net Debt 677 658 700 YoY change 3% • The capex for the quarter was Rs 54 Crore, which was primarily utilized towards the upcomi
Slide 33: Earnings conference call details
Date : July 31st, 2025 Diamond Pass Log-In Time : 05:00 pm IST To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: You will receive dial in numbers, passcode and a pin for the concall on the r
Slide 34: Thank you for your time
Jubilant Ingrevia Limited is a globally integrated Life Sciences & For Investors: Specialty Chemicals company, serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers. It has a broad Pavleen Taneja portfolio of over 130+ products and customized solutions that are Jubilant